TransMedics Group, Inc. — Director's Dealing 2023

Jan 18, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2023-01-17

Reporting Person: Carey John F (VP of Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-17	Common Stock	M	1410	$38.46	Acquired	15530	Direct
2023-01-17	Common Stock	S	63	$60.72	Disposed	15467	Direct
2023-01-17	Common Stock	S	446	$61.77	Disposed	15021	Direct
2023-01-17	Common Stock	S	338	$62.48	Disposed	14683	Direct
2023-01-17	Common Stock	S	449	$63.70	Disposed	14234	Direct
2023-01-17	Common Stock	S	114	$64.30	Disposed	14120	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-17	Stock Option (Right to Buy)	$38.46	M	1410	Disposed	2031-02-24	Common Stock (1410)	Direct

Footnotes

F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $60.12 to $61.07, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $61.18 to $62.17, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $62.18 to $63.17, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $63.19 to $64.18, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F6: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $64.19 to $64.52, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F7: The amount of securities directly owned by the Reporting Person includes 276 shares of common stock acquired under the TransMedics Group, Inc. 2019 Employee Stock Purchase Plan.

F8: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021.